PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance

(2014) Feda Azab et al.   BRITISH JOURNAL OF HAEMATOLOGY

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

(2013) Pradip De et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

(2013) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

(2013) V Munugalavadla et al.   ONCOGENE

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules

(2013) E Leich et al.   Blood Cancer Journal

PDK1 Signaling Toward PLK1-MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy

(2013) J. Tan et al.   Cancer Discovery

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes

(2012) Ipsita Pal et al.   ACTA PHARMACOLOGICA SINICA

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

(2012) Torsten Steinbrunn et al.   BRITISH JOURNAL OF HAEMATOLOGY

PI3K Pathway Inhibitors: Better Not Left Alone

(2012) Ben Markman et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting the PI3K signaling pathway in cancer therapy

(2012) Chandra Bartholomeusz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype

(2012) C Stengel et al.   LEUKEMIA

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

(2012) S Z Usmani et al.   LEUKEMIA

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

(2012) Heinz Ludwig et al.   LEUKEMIA RESEARCH

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

GenomeRNAi: a database for cell-based and in vivo RNAi phenotypes, 2013 update

(2012) Esther E. Schmidt et al.   NUCLEIC ACIDS RESEARCH

Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

(2012) Vijay Ramakrishnan et al.   PLoS One

Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations

(2012) J Glassford et al.   Blood Cancer Journal

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Many Multiple Myelomas: Making More of the Molecular Mayhem

(2011) M. Chesi et al.   Hematology-American Society of Hematology Education Program

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585

(2010) Thorsten Stühmer et al.   BRITISH JOURNAL OF HAEMATOLOGY

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

(2010) Qing-Bai She et al.   CANCER CELL

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Activity of any class IA PI3K isoform can sustain cell proliferation and survival

(2010) L. C. Foukas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma

(2009) Said I. Ismail et al.   LEUKEMIA RESEARCH

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

(2008) Philipp Baumann et al.   EXPERIMENTAL CELL RESEARCH

The p110  isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 

(2008) J. Guillermet-Guibert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA